Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
SAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, and present virtually on December 5, 2024 at the Emerging Growth Conference.
Participation Instructions for Jaguar Health's In-Person Presentation at NobleCon20
When: Tuesday, December 3, 2024 at 10:30 - 10:55 AM Eastern Standard Time
Where: Presentation Room 3, Florida Atlantic University, Executive Education Complex, Boca Raton, Florida
Registration link for conference: Click Here
Replay: A video webcast of the presentation will be available the following day as part of a complete catalog of presentations available at www.nobleconference.com and on Noble's Channelchek investor portal: www.channelchek.com. The webcast will be archived on the NobleCon website and on Channelchek.com for 90 days following the event.
Participation Instructions for Jaguar Health's Virtual Presentation at the Emerging Growth Conference
When: Thursday, December 5, 2024 from 10:50 - 11:20 AM Eastern Standard Time
Where: Online (Click Here)
Registration link for conference: Click Here
Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at NobleCon20 and at the December 2024 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com